Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.

Grumbach IM, Mayer IA, Uddin S, Lekmine F, Majchrzak B, Yamauchi H, Fujita S, Druker B, Fish EN, Platanias LC.

Br J Haematol. 2001 Feb;112(2):327-36.

PMID:
11167825
2.

Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.

Fernandez-Luna JL.

Apoptosis. 2000 Oct;5(4):315-8. Review.

PMID:
11227211
3.

Physiological signals and oncogenesis mediated through Crk family adapter proteins.

Feller SM, Posern G, Voss J, Kardinal C, Sakkab D, Zheng J, Knudsen BS.

J Cell Physiol. 1998 Dec;177(4):535-52. Review.

PMID:
10092207
4.

The p38 mitogen-activated protein kinase pathway and its role in interferon signaling.

Platanias LC.

Pharmacol Ther. 2003 May;98(2):129-42. Review.

PMID:
12725866
5.
6.

Signal transduction pathways involved in BCR-ABL transformation.

Sawyers CL.

Baillieres Clin Haematol. 1997 Jun;10(2):223-31. Review.

PMID:
9376661
7.

Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells.

Verma A, Platanias LC.

Leuk Lymphoma. 2002 Apr;43(4):703-9. Review.

PMID:
12153154
8.

Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.

Redig AJ, Vakana E, Platanias LC.

Leuk Lymphoma. 2011 Feb;52 Suppl 1:45-53. doi: 10.3109/10428194.2010.546919. Review.

PMID:
21299459
9.

Molecular pathophysiology of chronic myelogenous leukemia.

Turhan AG, Solary E, Vainchenker W, Dusanter-Fourt I.

Hematol Cell Ther. 1998 Oct;40(5):217-21. Review.

PMID:
9844814
10.

The interferon-alpha revival in CML.

Talpaz M, Mercer J, Hehlmann R.

Ann Hematol. 2015 Apr;94 Suppl 2:S195-207. doi: 10.1007/s00277-015-2326-y. Epub 2015 Mar 27. Review.

PMID:
25814086
11.

Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase.

Guilhot F, Lacotte-Thierry L.

Hematol Cell Ther. 1998 Oct;40(5):237-9. Review.

PMID:
9844819
12.

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.

Talpaz M, Hehlmann R, Quintás-Cardama A, Mercer J, Cortes J.

Leukemia. 2013 Apr;27(4):803-12. doi: 10.1038/leu.2012.313. Epub 2012 Nov 7. Review.

13.

[Analysis of IFN-alpha inducible genes in human chronic myelogenous leukemia cell line KT-1].

Takeuchi K.

Rinsho Ketsueki. 2003 Feb;44(2):65-9. Review. Japanese. No abstract available.

PMID:
12692977
14.

[Signaling pathway of macrophage colony-stimulating factor receptor].

Kimura F, Sato Y, Ota A, Nakamura Y, Nagata N, Motoyoshi K.

Rinsho Ketsueki. 1997 Mar;38(3):189-92. Review. Japanese. No abstract available.

PMID:
9095655
15.

[Signal transduction BCR-ABL fusion protein: analysis of BCR-ABL functional domains].

Tauchi T, Okabe S, Oyashiki K, Sotoyama K.

Rinsho Ketsueki. 1998 Feb;39(2):81-2. Review. Japanese. No abstract available.

PMID:
9545803
16.

Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia.

Berger A, Sexl V, Valent P, Moriggl R.

Oncotarget. 2014 Oct 30;5(20):9564-76. Review.

17.

[Intracellular signalization and inflammation: variations for an intracellular symphony. 1st movement].

Carreno MP.

Rev Med Interne. 1999 Sep;20(9):829-32. Review. French.

PMID:
10522312
18.

The role of CT10 regulation of kinase-like in cancer.

Guo C, Liu S, Sun MZ.

Future Oncol. 2014 Dec;10(16):2687-97. doi: 10.2217/fon.14.199. Review.

PMID:
25531052

Supplemental Content

Support Center